Compression Therapy of the Lower Limbs in Patients With Decompensated Heart Failure

Launched by FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL CLÍNICO DE VALENCIA · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of compression therapy on the lower limbs in patients with a condition called decompensated heart failure, which means the heart is not pumping well and causing fluid buildup in the body. The trial aims to see if adding compression therapy to the standard treatment of a medication called furosemide (a diuretic that helps remove excess fluid) improves symptoms and safety for patients. Participants will be randomly assigned to either receive just furosemide or furosemide along with lower limb compression therapy for up to 72 hours.

To participate, individuals must be at least 18 years old and diagnosed with acute decompensated heart failure within the last four days. They should have been treated with furosemide and show signs of fluid retention, such as swelling in the legs. However, those with severe kidney issues, certain heart conditions, or previous problems with compression bandages cannot take part in the trial. If eligible, participants can expect close monitoring by healthcare professionals and guidance throughout the study. This trial is currently recruiting and welcomes all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or older.
• • Patient with clinical judgment of acute decompensated heart failure in the first 96 hours from the start of parenteral diuretic treatment.
• • Patient treated with furosemide at least 40 mg in the last 24 hours.
• • NT-proBNP levels\>1000 pg/ml at least 1 time since the onset of decompensation.
• • Presence of tibio-malleolar edema at least grade II/IV at the time of inclusion.
• • Inferior vena cava (IVC) diameter on ultrasonography ≤21 mm at the time of the "screening" visit.
• Exclusion Criteria:
• • Being admitted to the Intensive Care Unit.
• • Renal transplant, chronic renal failure stage 5 (eGFR \<15 ml/min/1.73m2) or being included in dialysis program (peritoneal/hemodialysis) or in need of ultrafiltration.
• • Absence of peripheral pulses.
• • Ankle brachial index (ABI) \<0.9.
• • History of severe peripheral artery disease.
• • Previous intolerance to compressive bandaging.
• • HF secondary to acute myocardial infarction.